Navigation Links
PDL BioPharma Receives Letter from Genentech Relating to European Patents
Date:8/13/2010

INCLINE VILLAGE, Nev., Aug. 13 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-Looking Statements

This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

  • The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
  • The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.;
  • The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
  • Changes in any of the other assumptions on which PDL's projected royalty revenues are based;
  • The outcome of pending litigation or disputes; and
  • The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" section of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CeNeRx BioPharma Completes $13 Million Series C Financing
2. Almac Launch Biomarkers for Biopharma
3. Health Outcomes Data Essential to Biopharmaceutical Sales Process
4. Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing
5. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
6. Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences
7. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
8. R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds
9. PDL BioPharma To Hold Annual Meeting of Stockholders on June 9, 2010
10. R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
11. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Novavax, Inc., (Nasdaq: NVAX ) today announced that ... its RSV F protein recombinant nanoparticle vaccine candidate (RSV F ... in the journal Vaccine (the data ... conferences). The Company previously announced top line results ... RSV F Vaccine with the goal of protecting infants from ...
(Date:6/3/2017)...  Eli Lilly and Company (NYSE: ... Phase 3 MONARCH 2 study showed that abemaciclib, ... combination with fulvestrant, significantly improved progression-free survival (PFS) ... with hormone-receptor-positive (HR+), human epidermal growth factor receptor ... or progressed after endocrine therapy (median PFS, 16.4 ...
(Date:5/30/2017)... May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... Global Healthcare Conference on Tuesday, June 13, 2017, in ... , Hill-Rom,s president and chief executive officer, is scheduled to ... audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . A ... the live event through September 13, 2017. ...
Breaking Medicine Technology:
(Date:6/20/2017)... MA (PRWEB) , ... June 20, 2017 , ... Kenneth ... International AIDS Society (JIAS). , Dr. Mayer, who joined the JIAS Editorial Board ... is the founding Medical Research Director of Fenway Health and Co-Chair of ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Leading dental clinicians, ... imaging technology with the VATECH PaX-i and Anatomage systems. With advanced digital images and ... they can place dental implants precisely and restore oral health for those who are ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... Clinical Innovation Catalyst program focused on finding product improvements that could reduce ... in their throats when they need help breathing or to provide medication. Sometimes, ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... staffing agency, recently became re-accredited by the Joint Commission, which accredits ... Commission accreditation and certification is recognized nationwide as a symbol of quality that ...
(Date:6/20/2017)... ... 20, 2017 , ... The law firm of Momkus McCluskey Roberts LLC ... of the DuPage County Bar Association’s Board of Directors. Cassioppi officially took on the ... Drake in Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also ...
Breaking Medicine News(10 mins):